Skip to main content
. 2022 May 16;132(10):e145343. doi: 10.1172/JCI145343

Figure 6. PRAME restoration and immune infiltrates change by EZH2 inhibitor in an Ezh2-mutant in vivo lymphoma model.

Figure 6

(A) Serially sectioned tissues were stained with H&E, PRAME, CD3, CD4, FOXP3, and granzyme B (×20 and ×400 original magnification). Scale bar: 1 mm. (B) Comparison of intensity for PRAME and proportions of CD3-, CD4-, FOXP3-, and granzyme B–positive cells between vehicle and EPZ011989 treatment. Positive cells were counted in 3 independent high-power fields (*P < 0.05, **P < 0.01). (C) Spleen weight comparison between vehicle and EZH2 inhibitor treatment group. (D) Representative images of spleens from mice euthanized after 3 months of treatment. (E) H3K27me3 expression of splenocytes 3 months after treatment with vehicle or EZH2 inhibitor. Representative histogram (left) and MFI (right).